seed
Stage
1
Investors
About
MontA Biosciences develops a second-generation systemic TLR7 agonist formulated with proprietary lipid nanoparticles to target immune cells and convert immune cold tumors into hot tumors, enhancing the efficacy of cancer immunotherapy.
Explore MontA Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.